Euclidean Capital LLC Vir Biotechnology, Inc. Transaction History

Euclidean Capital LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$21.19 - $40.01 $853,045 - $1.61 Million	-40,257 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$30.97 - $54.03 $1.25 Million - $2.18 Million	40,257 New	40,257 $1.69 Million
Q3 2021 Nov 15, 2021	SELL	$34.9 - $54.54 $902,723 - $1.41 Million	-25,866 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$38.75 - $51.0 $77 - $102	2 Added 0.01%	25,866 $1.22 Million
Q1 2021 May 17, 2021	BUY	$26.34 - $83.07 $681,257 - $2.15 Million	25,864 New	25,864 $1.33 Million

225

88.2M

177K

182K

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.18B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Euclidean Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Euclidean Capital LLC with notifications on news.